Announced Thu, 30 Apr · 13:09 IST
Fosun Pharma declares zero share encumbrance for FY26
Compliance View source PDF
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.8%1-day move
₹1756.00
prior close
₹1754.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.0-0.1-0.3-0.2+3.8+1.1+3.0+6.5+8.5+6.8+32.4+30.6+40.9—
Up moveDown movePending
AI summary
Shanghai Fosun Pharmaceutical, the promoter of Gland Pharma, has filed its annual declaration under SEBI's Takeover Regulations (Reg 31(4)) confirming that the promoter and promoter group did not create any encumbrance (pledge, lien, etc.) on their shares during FY26. The number of promoter shares pledged stood at NIL on both April 1, 2025 and March 31, 2026. This is a routine yearly compliance filing with no change in encumbrance status.
Likely market impact
Routine compliance filing. Zero pledged shares means no near-term risk of forced sale or margin call on promoter stake. Neutral for the stock.